Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.9550 (7.14%) ($7.9550 - $7.9550) on Wed. Aug. 10, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.28% (three month average) | RSI | 61 | Latest Price | $7.9550(7.14%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 5.7% a day on average for past five trading days. | Weekly Trend | TGTX advances 6.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) QQQ(86%) ACES(85%) ICLN(76%) XBI(76%) ARKG(72%) | Factors Impacting TGTX price | TGTX will decline at least -3.64% in a week (0% probabilities). UUP(-43%) TBT(-32%) USO(-7%) XOP(-3%) XLE(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.64% (StdDev 7.28%) | Hourly BBV | 1.5 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $7.11(11.88%) | 10 Day Moving Average | $6.57(21.08%) | 20 Day Moving Average | $6.46(23.14%) | To recent high | 0% | To recent low | 113% | Market Cap | $1.007b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |